Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study

• Váldodahkkit: Ingrid Herta Rotstein Grein (Dahkki), Natalia Balera Ferreira Pinto (Dahkki), Noortje Groot (Dahkki), Camila Bertini Martins (Dahkki), Aline Lobo (Dahkki), Nadia Emi Aikawa (Dahkki), Cassia Barbosa (Dahkki), Maria Teresa Terreri (Dahkki), Aline Coelho Moreira da Fraga (Dahkki), Sheila Knupp Feitosa de Oliveira (Dahkki), Flavio Sztajnbok (Dahkki), Luciana B. Paim Marques (Dahkki), Aline Garcia Islabão (Dahkki), Simone Appenzeller (Dahkki), Blanca Bica (Dahkki), Juliana de Oliveira Sato (Dahkki), Claudia Saad Magalhães (Dahkki), Virgínia Ferriani (Dahkki), Hella Pasmans (Dahkki), Rutger Schepp (Dahkki), Fiona van der Klis (Dahkki), Sytze de Roock (Dahkki), Nico Wulffraat (Dahkki), Gecilmara Salviato Pileggi (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: BMC, 2020-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Background Concerns about the safety and efficacy of vaccines in patients with autoimmune diseases (AID) have led to contradictions and low vaccination coverage in this population, who are at a higher risk of infections, including by human papillomavirus (HPV). Although HPV vaccines have be...